Latest News and Press Releases

SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark Blue...

SUFFERN, N.Y., March 09, 2021 (GLOBE NEWSWIRE) -- WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus (BE), pre-cancer and cancerous cells in the esophagus, has received a...

SUFFERN, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now...

Veterans now have access to WATS3D life-saving technology in the VA and community settings SUFFERN, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics has been awarded GSA Contract...

The addition of WATS3D to the screening process for BE resulted in approximately 3 fewer cancers and 3 fewer cancer deaths per 1,000 people screened SUFFERN, N.Y., Aug. 25, 2020 (GLOBE NEWSWIRE) --...

WATS3D diagnostic platform for screening and surveillance ofBarrett’s esophagus now available to 800,000 members SUFFERN, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics, Inc. is now...

SUFFERN, N.Y., June 16, 2020 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform used to identify precancerous cells in the esophagus, has been deemed as a safe and effective adjunctive to...

- Newly issued coverage statement on diagnostic platform for screening and surveillance of Barrett’s esophagus - SUFFERN, N.Y., April 02, 2020 (GLOBE NEWSWIRE) -- Effective Jan. 21, 2020 – CDx...

SUFFERN, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- CDx Diagnostics, developer of the WATS3D diagnostic platform for the screening and surveillance of Barrett’s esophagus (BE), a known precursor to...

- Study shows that the addition of WATS3D increased the detection of residual/recurrent intestinal metaplasia by 79% and associated dysplasia by 224% - SUFFERN, N.Y., May 18, 2019 (GLOBE NEWSWIRE)...